Chrysalis BioTherapeutics Overview

  • Year Founded
  • 1995

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series A
  • (Upcoming)

  • Investors
  • 2

Chrysalis BioTherapeutics General Information

Description

Developer of regenerative anti-inflammatory drugs designed to repair damaged tissues and reduce inflammatory responses associated with severe medical conditions. The company offers stem cell and endothelial progenitor cell-activating therapies for tissue regeneration, radiation injury mitigation, and inflammation management, enabling healthcare providers and patients to support recovery from acute lung injury, the effects of cancer treatment, and radiation exposure.

Contact Information

Formerly Known As
Chrysalis BioTechnology
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1700 Strand Street
  • Suite 2.302
  • Galveston, TX 77550
  • United States
+1 (281)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1700 Strand Street
  • Suite 2.302
  • Galveston, TX 77550
  • United States
+1 (281)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Chrysalis BioTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) Upcoming Clinical Trials - General
5. Seed Round 22-Mar-2024 Completed Clinical Trials - General
4. Grant 10-Jun-2020 Completed Clinical Trials - General
3. Grant 05-Jun-2020 Completed Clinical Trials - General
2. Grant 09-May-2016 $3M Completed Clinical Trials - General
1. Merger/Acquisition 05-Aug-2004 $34.5M Completed Clinical Trials - General
To view Chrysalis BioTherapeutics’s complete valuation and funding history, request access »

Chrysalis BioTherapeutics Patents

Chrysalis BioTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260165965-A1 Stabilized tp508 formulations Pending 17-Dec-2024
WO-2024211447-A1 Tp508 mrnas Inactive 03-Apr-2023
CA-3179798-A1 Tp508 acute therapy for patients with respiratory virus infection Pending 07-Apr-2020
EP-4132948-A1 Tp508 acute therapy for patients with respiratory virus infection Inactive 07-Apr-2020
EP-4132948-A4 Tp508 acute therapy for patients with respiratory virus infection Inactive 07-Apr-2020 C12Y304/21005
To view Chrysalis BioTherapeutics’s complete patent history, request access »

Chrysalis BioTherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Chrysalis BioTherapeutics Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
National Institute Of Allergy and Infectious Diseases Government
To view Chrysalis BioTherapeutics’s complete investors history, request access »

Chrysalis BioTherapeutics FAQs

  • When was Chrysalis BioTherapeutics founded?

    Chrysalis BioTherapeutics was founded in 1995.

  • Where is Chrysalis BioTherapeutics headquartered?

    Chrysalis BioTherapeutics is headquartered in Galveston, TX.

  • What is the size of Chrysalis BioTherapeutics?

    Chrysalis BioTherapeutics has 5 total employees.

  • What industry is Chrysalis BioTherapeutics in?

    Chrysalis BioTherapeutics’s primary industry is Drug Discovery.

  • Is Chrysalis BioTherapeutics a private or public company?

    Chrysalis BioTherapeutics is a Private company.

  • What is Chrysalis BioTherapeutics’s current revenue?

    The current revenue for Chrysalis BioTherapeutics is .

  • How much funding has Chrysalis BioTherapeutics raised over time?

    Chrysalis BioTherapeutics has raised $515K.

  • Who are Chrysalis BioTherapeutics’s investors?

    National Institutes of Health and National Institute Of Allergy and Infectious Diseases have invested in Chrysalis BioTherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process